Canopy Growth's September Showdown: A Reverse Split, a Restatement, and a European Growth Bet

Canopy Growth beats Q1 estimates, narrows losses, and targets European growth, but shares trade near lows ahead of a reverse split vote.

The gap between Canopy Growth's operational trajectory and its share price has rarely been wider. The Canadian cannabis producer just delivered a quarter that beat analyst estimates by a wide margin, narrowed its losses sharply, and confirmed it is banking on higher-margin European markets to fuel its next phase of growth. Yet the stock trades at roughly 0.8864 euros, down 56 percent from its 52-week high of 2.00 euros, and investors are being asked to approve a reverse stock split that underscores just how far the equity has fallen.

That vote arrives at the company's annual meeting on September 25, with management proposing a consolidation ratio between one-for-five and one-for-fifteen, at the board's discretion. The move is mechanical — it changes nothing about the underlying value of the company — but it signals that the share price has sunk low enough to raise regulatory or listing concerns. Canopy Growth needs a quorum of 33 1/3 percent of outstanding shares for the vote to be valid, and it is actively encouraging early voting to avoid the added costs of a postponement.

A Quarter That Beat the Street

The numbers themselves tell a story of stabilization. For the first quarter of fiscal 2027, reported on August 7, Canopy Growth posted net revenue of 81.2 million Canadian dollars, up 13 percent year over year and well ahead of the 58.9 million Canadian dollars analysts had expected. The per-share loss shrank to 0.02 Canadian dollars from 0.14 Canadian dollars in the year-ago quarter.

Growth was broad-based. The Canadian medical cannabis business advanced 22 percent, while the Storz & Bickel vaporizer division gained 6 percent. Cost reductions and the integration of MTL Cannabis, acquired in March 2026, helped trim the quarterly loss to 14.6 million Canadian dollars.

The MTL deal is already paying off faster than expected. Canopy Growth said it has realized 8 million Canadian dollars of the 10 million Canadian dollars in annual synergies it targets from the acquisition, and management reaffirmed its goal of reaching positive adjusted EBITDA in fiscal 2027.

The European Pivot

CEO Luc Mongeau used the Canaccord Genuity growth conference on August 11 to lay out the international ambition: lifting the annual revenue run-rate in Europe from roughly 40 million Canadian dollars to between 100 million and 150 million Canadian dollars. The strategy rests on the "asset-right" model — focusing on certified production facilities and regional partnerships to keep fixed costs down while meeting the strict requirements of prescription-based medical markets in Europe and Australia.

A key piece of that puzzle fell into place on August 14, when Canopy Growth renewed its EU-GMP certification for its cultivation facility in Kincardine, Ontario. The certification is a prerequisite for exporting medical cannabis to growth markets such as Germany and Poland, and management sees it as the foundation for an uninterrupted supply chain. International revenue grew 10 percent in the quarter, and the renewed certification is meant to protect that momentum.

Two Clouds on the Horizon

The bull case, however, comes with caveats that are hard to ignore. In its definitive proxy statement, Canopy Growth disclosed that certain historical financial statements for fiscal years 2024 and 2025 can no longer be relied upon due to a technical, non-cash error in the classification of certain equity-linked warrants. Management frames it as an accounting classification issue rather than an operational problem, but it chips away at confidence in reporting quality at a company already under heightened scrutiny.

The auditor situation adds another layer. The previous audit firm withdrew from the cannabis sector, and shareholders will be asked to approve a new auditor at the September meeting alongside the board re-election and the reverse split.

The balance sheet, meanwhile, offers some breathing room. As of June 30, 2026, Canopy Growth held 337 million Canadian dollars in cash and cash equivalents against 211.4 million Canadian dollars in long-term debt — a structure that leaves operational flexibility, even if it is no cause for complacency.

Speculation in the Air

The broader sector is buzzing with consolidation talk after Curaleaf's 272-million-dollar takeover offer for Aurora Cannabis on August 13, prompting speculation about whether Canopy Growth could be next in someone's sights. That speculation, based on media reports rather than confirmed negotiations, should be treated with caution.

Analysts have trimmed their price targets — the consensus fell 13 percent to 2.02 Canadian dollars after the earnings release — but that still sits well above the current trading level. The 14-day RSI stands at 57.5, pointing to neutral-to-slightly-positive market sentiment, and the stock has gained 12 percent over the past 30 days, including a 1.9 percent advance on the latest trading day.

The central question for the coming quarters remains whether Canopy Growth can deliver that positive adjusted EBITDA. The September vote will settle the split ratio, but the real test is whether the operational progress — the European push, the MTL synergies, the narrowing losses — can eventually close the gap with a share price that has yet to reflect any of it. With annual volatility of 47 percent, this remains a stock for investors with steady nerves.